Advanced search
Publication Cover
Molecular and Cellular Biology Volume 29, 2009 - Issue 12
Submit an article Journal homepage
107
Views
133
CrossRef citations to date
0
Altmetric
Article

A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis

Kim Pedersen1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain
,
Pier-Davide Angelini1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain;2 Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Campus de la UAB, 08193Bellaterra, Spain
,
Sirle Laos1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain
,
Alba Bach-Faig1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain
,
Matthew P. Cunningham1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain
,
Cristina Ferrer-Ramón1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain
,
Antonio Luque-García1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain
,
Jesús García-Castillo1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain
,
Josep Lluis Parra-Palau1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain
,
Maurizio Scaltriti1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain
,
Santiago Ramón y Cajal1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain
,
José Baselga1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain
&
Joaquín Arribas1 Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035Barcelona, Spain;2 Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Campus de la UAB, 08193Bellaterra, Spain;3 Institució Catalana de Recerca i Estudis Avançats, 08010Barcelona, SpainCorrespondence[email protected]
 show all
Pages 3319-3331 | Received 25 Nov 2008, Accepted 03 Apr 2009, Published online: 21 Mar 2023

Citations (133)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Pooja Advani, Lauren Cornell, Saranya Chumsri & Alvaro Moreno-Aspitia. (2015) Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Breast Cancer: Targets and Therapy 7, pages 321-335.
Read now
Hannah Gautrey, Claire Jackson, Anna-Lena Dittrich, David Browell, Thomas Lennard & Alison Tyson-Capper. (2015) SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells. RNA Biology 12:10, pages 1139-1151.
Read now
Anna Tessari, Dario Palmieri & Serena Di Cosimo. (2014) Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmacogenomics and Personalized Medicine 7, pages 1-19.
Read now
Deniz Tural, Emre Akar, Hasan Mutlu & Saadettin Kilickap. (2014) P95 HER2 fragments and breast cancer outcome. Expert Review of Anticancer Therapy 14:9, pages 1089-1096.
Read now
Pier-Luigi Lollini, Federica Cavallo, Carla De Giovanni & Patrizia Nanni. (2013) Preclinical vaccines against mammary carcinoma. Expert Review of Vaccines 12:12, pages 1449-1463.
Read now
Elda Tagliabue, Andrea Balsari, Manuela Campiglio & Serenella M Pupa. (2010) HER2 as a target for breast cancer therapy. Expert Opinion on Biological Therapy 10:5, pages 711-724.
Read now

Articles from other publishers (127)

Michael Galogre, Dmitry Rodin, Mikhail Pyatnitskiy, Melissa Mackelprang & Igor Koman. (2023) A review of HER2 overexpression and somatic mutations in cancers. Critical Reviews in Oncology/Hematology 186, pages 103997.
Crossref
Zikuan Gu, Zhanchen Guo, Song Gao, Lingrui Huang & Zhen Liu. (2023) Hierarchically Structured Molecularly Imprinted Nanotransducers for Truncated HER2-Targeted Photodynamic Therapy of Therapeutic Antibody-Resistant Breast Cancer. ACS Nano.
Crossref
Xiao-Nan Zhang, Ya Gao, Xi-Ya Zhang, Ning-Jie Guo, Wen-Qing Hou, Shu-Wu Wang, Yi-Chao Zheng, Ning Wang, Hong-Min Liu & Bo Wang. (2023) Detailed curriculum vitae of HER2-targeted therapy. Pharmacology & Therapeutics 245, pages 108417.
Crossref
Devin L. Wakefield, Ottavia Golfetto, Raphael Jorand, Sunetra Biswas, Kassondra Meyer, Kendra N. Avery, Cindy Zer, Eliedonna E. Cacao, Steven J. Tobin, Ian J. Talisman, John C. Williams & Tijana Jovanovic-Talisman. (2023) Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands. Frontiers in Medicine 10.
Crossref
Chuqi Wang, Tian Li, Wenyan Fu & Shi Hu. 2023. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies 75 81 .
Esmaeil Dorraji, Elin Borgen, Dario Segura-Peña, Puneet Rawat, Eva Smorodina, Claire Dunn, Victor Greiff, Nikolina Sekulić, Hege Russnes & Jon Amund Kyte. (2022) Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform. Cancers 14:19, pages 4859.
Crossref
Soeun Park, Jung Min Park, Minsu Park, Dongmi Ko, Seongjae Kim, Juyeon Seo, Kee Dal Nam, Eunsun Jung, Lee Farrand, Yoon-Jae Kim, Ji Young Kim & Jae Hong Seo. (2022) β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features. Cancer Cell International 22:1.
Crossref
Manuel Gámez-Chiachio, David Sarrió & Gema Moreno-Bueno. (2022) Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers 14:18, pages 4543.
Crossref
Jack D. Godfrey, Daniel Hejazi, Xiaofei Du, Cenfu Wei, Eshaan Rao & Christopher M. Gomez. (2022) HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA. International Journal of Molecular Sciences 23:17, pages 9549.
Crossref
Ilana Schlam, Paolo Tarantino & Sara M. Tolaney. (2022) Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. Cancers 14:16, pages 3996.
Crossref
Mark M. Moasser. (2022) Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions. Cancer Research 82:16, pages 2811-2820.
Crossref
Zhengxing Zhou, Chengmin Zhang, Zhiyuan Ma, Hu Wang, Biguang Tuo, Xiaoming Cheng, Xuemei Liu & Taolang Li. (2022) Pathophysiological role of ion channels and transporters in HER2-positive breast cancer. Cancer Gene Therapy 29:8-9, pages 1097-1104.
Crossref
Adam L. Maddox, Matthew S. Brehove, Kiarash R. Eliato, Andras Saftics, Eugenia Romano, Michael F. Press, Joanne Mortimer, Veronica Jones, Daniel Schmolze, Victoria L. Seewaldt & Tijana Jovanovic-Talisman. (2022) Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. Cancers 14:11, pages 2795.
Crossref
Soeun Park, Yoon-Jae Kim, Jung Min Park, Minsu Park, Kee Dal Nam, Lee Farrand, Cong-Truong Nguyen, Minh Thanh La, Jihyae Ann, Jeewoo Lee, Ji Young Kim & Jae Hong Seo. (2021) The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells. Cell Death Discovery 7:1.
Crossref
Joshua D. Ginzel, Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, Jeffrey I. Everitt, Zachary C. Hartman, Erika J. Crosby, Lawrence S. Barak, Marc G. Caron, Jane Q. Chen, Neil E. Hubbard, Robert D. Cardiff, Alexander D. Borowsky, H. Kim Lyerly & Joshua C. Snyder. (2021) HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. Molecular Cancer Research 19:10, pages 1699-1711.
Crossref
Serenella M. Pupa, Francesca Ligorio, Valeria Cancila, Alma Franceschini, Claudio Tripodo, Claudio Vernieri & Lorenzo Castagnoli. (2021) HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. Cancers 13:19, pages 4778.
Crossref
Li-Chung Tsao, Jeremy Force & Zachary C. Hartman. (2021) Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Research 81:18, pages 4641-4651.
Crossref
Angelina T. Regua, Austin Arrigo, Daniel Doheny, Grace L. Wong & Hui-Wen Lo. (2021) Transgenic mouse models of breast cancer. Cancer Letters 516, pages 73-83.
Crossref
Hamid Maadi, Mohammad Hasan Soheilifar, Won-Shik Choi, Abdolvahab Moshtaghian & Zhixiang Wang. (2021) Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. Cancers 13:14, pages 3540.
Crossref
David K. Lau, Ian Y. Luk, Laura J. Jenkins, Andrew Martin, David S. Williams, Kael L. Schoffer, Fiona Chionh, Michael Buchert, Katrin Sjoquist, Alex Boussioutas, Sarah A. Hayes, Matthias Ernst, Andrew J. Weickhardt, Nick Pavlakis, Niall C. Tebbutt & John M. Mariadason. (2021) Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. Molecular Cancer Therapeutics 20:4, pages 704-715.
Crossref
Jill R. Crittenden, Theresa A. Gipson, Anne C. Smith, Hilary A. Bowden, Ferah Yildirim, Kyle B. Fischer, Michael Yim, David E. Housman & Ann M. Graybiel. (2021) Striatal transcriptome changes linked to drug‐induced repetitive behaviors. European Journal of Neuroscience 53:8, pages 2450-2468.
Crossref
Jung Min Park, Yoon-Jae Kim, Soeun Park, Minsu Park, Lee Farrand, Cong-Truong Nguyen, Jihyae Ann, Gibeom Nam, Hyun-Ju Park, Jeewoo Lee, Ji Young Kim & Jae Hong Seo. (2020) A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer. Molecular Cancer 19:1.
Crossref
Vic Hart, Hannah Gautrey, John Kirby & Alison Tyson-Capper. (2020) HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes. Oncotarget 11:46, pages 4338-4357.
Crossref
Insu Jeon, Jeong-Mi Lee, Kwang-Soo Shin, Taeseung Kang, Myung Hwan Park, Hyungseok Seo, Boyeong Song, Choong-Hyun Koh, Jeongwon Choi, Young Kee Shin, Byung-Seok Kim & Chang-Yuil Kang. (2020) Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses. Vaccines 8:3, pages 403.
Crossref
Ryuichi Fukuda, Alla Aharonov, Yu Ting Ong, Oliver A Stone, Mohamed El-Brolosy, Hans-Martin Maischein, Michael Potente, Eldad Tzahor & Didier YR Stainier. (2019) Metabolic modulation regulates cardiac wall morphogenesis in zebrafish. eLife 8.
Crossref
Andrej Gorbatenko, Rolf Søkilde, Ester E. Sorensen, Inga Newie, Helena Persson, Beatriz Morancho, Joaquin Arribas, Thomas Litman, Carlos Rovira & Stine Falsig Pedersen. (2019) HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503. Scientific Reports 9:1.
Crossref
Jürgen Scheller, Erika Engelowski, Jens M. Moll & Doreen M. Floss. (2019) Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics. Trends in Immunology 40:3, pages 258-272.
Crossref
Mehri Ghasabi, Behzad Mansoori, Ali Mohammadi, Pascal HG Duijf, Navid Shomali, Naghmeh Shirafkan, Ahad Mokhtarzadeh & Behzad Baradaran. (2018) MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. Journal of Cellular Physiology 234:3, pages 2152-2168.
Crossref
Siri Amanda Tvingsholm, Ditte Marie Brix & Tuula Kallunki. (2018) Molecular and Transcriptional Signatures for ErbB2-Induced Invasion. Current Pharmacology Reports 5:1, pages 43-55.
Crossref
Evgeniya A. Sokolova, Vladimir A. Vodeneev, Sergey M. Deyev & Irina V. Balalaeva. (2019) 3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development. Drug Discovery Today 24:1, pages 99-111.
Crossref
Hung-I Harry Chen, Yu-Chiao Chiu, Tinghe Zhang, Songyao Zhang, Yufei Huang & Yidong Chen. (2018) GSAE: an autoencoder with embedded gene-set nodes for genomics functional characterization. BMC Systems Biology 12:S8.
Crossref
Irene Rius Ruiz, Rocio Vicario, Beatriz Morancho, Cristina Bernadó MoralesEnrique J. Arenas, Sylvia HerterAnne Freimoser-Grundschober, Jitka SomandinJohannes SamOliver Ast, Águeda Martinez Barriocanal, Antonio Luque, Marta EscorihuelaIsmael Varela, Isabel CuartasPaolo Nuciforo, Roberta FasaniVicente Peg, Isabel RubioJavier Cortés, Violeta SerraSantiago Escriva-de-Romani, Jeff SperindeAhmed Chenna, Weidong HuangJohn WinslowJoan AlbanellJoan SeoaneMaurizio Scaltriti, Jose Baselga, Josep Tabernero, Pablo UmanaMarina BacacCristina SauraChristian Klein & Joaquín Arribas. (2018) p95HER2–T cell bispecific antibody for breast cancer treatment. Science Translational Medicine 10:461.
Crossref
Babak Nami, Hamid Maadi & Zhixiang Wang. (2018) Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. Cancers 10:10, pages 342.
Crossref
Jeff Sperinde, Weidong Huang, Aki Vehtari, Ahmed Chenna, Pirkko-Liisa Kellokumpu-Lehtinen, John Winslow, Petri Bono, Yolanda S. Lie, Christos J. Petropoulos, Jodi Weidler & Heikki Joensuu. (2018) p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. Clinical Cancer Research 24:13, pages 3046-3052.
Crossref
Saranya Chumsri, Jeff Sperinde, Heshan Liu, Joseph Gligorov, Jean-Philippe Spano, Martine Antoine, Alvaro Moreno Aspitia, Winston Tan, John Winslow, Christos J. Petropoulos, Ahmed Chenna, Michael Bates, Jodi Marie Weidler, Weidong Huang, Amylou Dueck & Edith A. Perez. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clinical Cancer Research 24:13, pages 3053-3058.
Crossref
Athena Georgilis, Sabrina Klotz, Christopher J. Hanley, Nicolas Herranz, Benedikt Weirich, Beatriz Morancho, Ana Carolina Leote, Luana D'Artista, Suchira Gallage, Marco Seehawer, Thomas Carroll, Gopuraja Dharmalingam, Keng Boon Wee, Marco Mellone, Joaquim Pombo, Danijela Heide, Ernesto Guccione, Joaquín Arribas, Nuno L. Barbosa-Morais, Mathias Heikenwalder, Gareth J. Thomas, Lars Zender & Jesús Gil. (2018) PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells. Cancer Cell 34:1, pages 85-102.e9.
Crossref
Carlos D. Martins, Chiara Da Pieve, Thomas A. Burley, Rhodri Smith, Daniela M. Ciobota, Louis Allott, Kevin J. Harrington, Wim J.G. Oyen, Graham Smith & Gabriela Kramer-Marek. (2018) HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. Clinical Cancer Research 24:8, pages 1853-1865.
Crossref
Chi-Chih Kang, Toby M. Ward, Jessica Bockhorn, Courtney Schiffman, Haiyan Huang, Mark D. Pegram & Amy E. Herr. (2018) Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution. npj Precision Oncology 2:1.
Crossref
Henrik Devitt Møller, Marghoob Mohiyuddin, Iñigo Prada-Luengo, M. Reza Sailani, Jens Frey Halling, Peter Plomgaard, Lasse Maretty, Anders Johannes Hansen, Michael P. Snyder, Henriette Pilegaard, Hugo Y. K. Lam & Birgitte Regenberg. (2018) Circular DNA elements of chromosomal origin are common in healthy human somatic tissue. Nature Communications 9:1.
Crossref
Jennifer L. Hsu & Mien-Chie Hung. 2018. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways 51 66 .
Renata Duchnowska, Jeff Sperinde, Bogumiła Czartoryska-Arłukowicz, Paulina Myśliwiec, John Winslow, Barbara Radecka, Christos Petropoulos, Regina Demlova, Marlena Orlikowska, Anna Kowalczyk, Istvan Lang, Barbara Ziółkowska, Sylwia Dębska-Szmich, Monika Merdalska, Aleksandra Grela-Wojewoda, Anton Żawrocki, Wojciech Biernat, Weidong Huang & Jacek Jassem. (2017) Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab. Oncotarget 8:61, pages 104149-104159.
Crossref
Rosa Martín-Pérez, Rosario Yerbes, Rocío Mora-Molina, Ana Cano-González, Joaquín Arribas, Massimiliano Mazzone, Abelardo López-Rivas & Carmen Palacios. (2017) Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis. Oncotarget 8:55, pages 93688-93703.
Crossref
Balazs T Nemeth, Zoltan V Varga, Wen Jin Wu & Pal Pacher. (2017) Trastuzumab cardiotoxicity: from clinical trials to experimental studies. British Journal of Pharmacology 174:21, pages 3727-3748.
Crossref
Isabelle Gingras, Géraldine Gebhart, Evandro de Azambuja & Martine Piccart-Gebhart. (2017) HER2-positive breast cancer is lost in translation: time for patient-centered research. Nature Reviews Clinical Oncology 14:11, pages 669-681.
Crossref
Arianna Palladini, Giordano Nicoletti, Alessia Lamolinara, Massimiliano Dall’Ora, Tania Balboni, Marianna L. Ianzano, Roberta Laranga, Lorena Landuzzi, Veronica Giusti, Claudio Ceccarelli, Donatella Santini, Mario Taffurelli, Enrico Di Oto, Sofia Asioli, Augusto Amici, Serenella M. Pupa, Carla De Giovanni, Elda Tagliabue, Manuela Iezzi, Patrizia Nanni & Pier-Luigi Lollini. (2017) HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. Oncotarget 8:33, pages 54444-54458.
Crossref
Babak Nami & Zhixiang Wang. (2017) HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance. Cancers 9:5, pages 40.
Crossref
Patricia V Elizalde, Rosalía I Cordo Russo, Maria F Chervo & Roxana Schillaci. (2016) ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocrine-Related Cancer 23:12, pages T243-T257.
Crossref
Inga Newie, Rolf Søkilde, Helena Persson, Thiago Jacomasso, Andrej Gorbatenko, Åke Borg, Michiel de Hoon, Stine F. Pedersen & Carlos Rovira. (2016) HER2-encoded mir-4728 forms a receptor-independent circuit with miR-21-5p through the non-canonical poly(A) polymerase PAPD5. Scientific Reports 6:1.
Crossref
Debora de Melo Gagliato, Denis Leonardo Fontes Jardim, Mario Sergio Pereira Marchesi & Gabriel N. Hortobagyi. (2016) Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget 7:39, pages 64431-64446.
Crossref
Hazem I. Assi, Rita E. Assi & Nagi S. El Saghir. (2016) Emerging Biomarkers of the Future: Changing Clinical Practice for 2020. Current Breast Cancer Reports 8:2, pages 60-72.
Crossref
Tamara S. Rodems, Mari Iida, Toni M. Brand, Hannah E. Pearson, Rachel A. Orbuch, Bailey G. Flanigan & Deric L. Wheeler. (2016) Adaptive responses to antibody based therapy. Seminars in Cell & Developmental Biology 50, pages 153-163.
Crossref
Ksenija Asić. (2016) Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies. Critical Reviews in Oncology/Hematology 97, pages 178-196.
Crossref
Ricardo H Alvarez, Javier Cortés, Mary Falzon, Michael Gandy, Luca Gianni, Nadia Harbeck & Martine PiccartMary Falzon & Michael Gandy. 2016. Handbook of HER2-Targeted Agents in Breast Cancer. Handbook of HER2-Targeted Agents in Breast Cancer 15 27 .
Beatriz Morancho, Águeda Martínez-Barriocanal, Josep Villanueva & Joaquín Arribas. (2015) Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Research 17:1.
Crossref
Shinya Matsuzaki, Kiyoshi Yoshino, Yutaka Ueda, Satoko Matsuzaki, Mamoru Kakuda, Akiko Okazawa, Tomomi Egawa-Takata, Eiji Kobayashi & Tadashi Kimura. (2015) Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives. Cancer Cell International 15:1.
Crossref
Zijia Sun, Yaqin Shi, Yan Shen, Lulu Cao, Wenwen Zhang & Xiaoxiang Guan. (2015) Analysis of different HER ‐2 mutations in breast cancer progression and drug resistance . Journal of Cellular and Molecular Medicine 19:12, pages 2691-2701.
Crossref
David M. Epstein & Elizabeth Buck. (2015) Old dog, new tricks: extracellular domain arginine methylation regulates EGFR function. Journal of Clinical Investigation 125:12, pages 4320-4322.
Crossref
Mei-Kuang Chen & Mien-Chie Hung. (2015) Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. FEBS Journal 282:19, pages 3693-3721.
Crossref
Irina Gromova, Pavel Gromov, Naoko Honma, Sudha Kumar, David Rimm, Maj-Lis Møller Talman, Vera Timmermans Wielenga & José M.A. Moreira. (2015) High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy. Molecular Oncology 9:8, pages 1636-1654.
Crossref
Efrosini Tsouko, Jun Wang, Daniel E. Frigo, Eylem Aydoğdu & Cecilia Williams. (2015) miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene . Carcinogenesis 36:9, pages 1051-1060.
Crossref
Rocio Vicario, Vicente Peg, Beatriz Morancho, Mariano Zacarias-Fluck, Junjie Zhang, Águeda Martínez-Barriocanal, Alexandra Navarro Jiménez, Claudia Aura, Octavio Burgues, Ana Lluch, Javier Cortés, Paolo Nuciforo, Isabel T. Rubio, Elisabetta Marangoni, James Deeds, Markus Boehm, Robert Schlegel, Josep Tabernero, Rebecca Mosher & Joaquín Arribas. (2015) Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLOS ONE 10:6, pages e0129876.
Crossref
M. F. Zacarias-Fluck, B. Morancho, R. Vicario, A. Luque Garcia, M. Escorihuela, J. Villanueva, I. T. Rubio & J. Arribas. (2015) Effect of Cellular Senescence on the Growth of HER2-Positive Breast Cancers. JNCI Journal of the National Cancer Institute 107:5, pages djv020-djv020.
Crossref
R. Duchnowska, J. Sperinde, A. Chenna, W. Huang, J. M. Weidler, J. Winslow, M. Haddad, A. Paquet, Y. Lie, T. Trojanowski, T. Mandat, A. Kowalczyk, B. Czartoryska-Ar ukowicz, B. Radecka, B. Jarosz, R. Staszkiewicz, E. Kalinka-Warzocha, M. Chudzik, W. Biernat & J. Jassem. (2015) Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro-Oncology.
Crossref
Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, Jeff Sperinde, Dominique Agbor-Tarh, Christine Campbell, Ahmed Chenna, John Winslow, Violeta Serra, Josep Lluis Parra, Ludmila Prudkin, José Jimenez, Claudia Aura, Nadia Harbeck, Lajos Pusztai, Catherine Ellis, Holger Eidtmann, Joaquin Arribas, Javier Cortes, Evandro de Azambuja, Martine Piccart & José Baselga. (2015) High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. Clinical Cancer Research 21:3, pages 569-576.
Crossref
Fresia Pareja, Gur Pines & Yosef Yarden. 2015. Receptor Tyrosine Kinases: Family and Subfamilies. Receptor Tyrosine Kinases: Family and Subfamilies 107 164 .
Wolfgang J. Köstler & Christoph C. Zielinski. 2015. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease 225 278 .
A. Dittrich, H. Gautrey, D. Browell & A. Tyson-Capper. (2014) The HER2 Signaling Network in Breast Cancer—Like a Spider in its Web. Journal of Mammary Gland Biology and Neoplasia 19:3-4, pages 253-270.
Crossref
Lorenzo Castagnoli, Manuela Iezzi, Gaia C. Ghedini, Valentina Ciravolo, Giulia Marzano, Alessia Lamolinara, Roberta Zappasodi, Patrizia Gasparini, Manuela Campiglio, Augusto Amici, Claudia Chiodoni, Arianna Palladini, Pier Luigi Lollini, Tiziana Triulzi, Sylvie Menard, Patrizia Nanni, Elda Tagliabue & Serenella M. Pupa. (2014) Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. Cancer Research 74:21, pages 6248-6259.
Crossref
Josep Lluís Parra-Palau, Beatriz Morancho, Vicente Peg, Marta Escorihuela, Maurizio Scaltriti, Rocio Vicario, Mariano Zacarias-Fluck, Kim Pedersen, Atanasio Pandiella, Paolo Nuciforo, Violeta Serra, Javier Cortés, José Baselga, Charles M. Perou, Aleix Prat, Isabel T. Rubio & Joaquín Arribas. (2014) Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. JNCI: Journal of the National Cancer Institute 106:11.
Crossref
Naveid A Ali, Jianmin Wu, Falko Hochgräfe, Howard Chan, Radhika Nair, Sunny Ye, Luxi Zhang, Ruth J Lyons, Mark Pinese, Hong Ching Lee, Nicola Armstrong, Christopher J Ormandy, Susan J Clark, Alexander Swarbrick & Roger J Daly. (2014) Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways. Breast Cancer Research 16:5.
Crossref
Alessandra Fabi, Marcella Mottolese & Oreste Segatto. (2014) Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic. Journal of Molecular Medicine 92:7, pages 681-695.
Crossref
Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Mojgan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumiła Czartoryska-Arłukowicz, Piotr J. Wysocki, Małgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwiniuk, Jolanta Żok, Michał Wiśniewski, Dorota Zuziak, Wojciech Biernat & Jacek Jassem. (2014) Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff. Clinical Cancer Research 20:10, pages 2805-2813.
Crossref
Jean-Christophe Thery, Jean-Philippe Spano, David Azria, Eric Raymond & Frédérique Penault Llorca. (2014) Resistance to human epidermal growth factor receptor type 2-targeted therapies. European Journal of Cancer 50:5, pages 892-901.
Crossref
K Pedersen, F Canals, A Prat, J Tabernero & J Arribas. (2013) PELO negatively regulates HER receptor signalling and metastasis. Oncogene 33:9, pages 1190-1197.
Crossref
Ditte Brix, Knut Clemmensen & Tuula Kallunki. (2014) When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase. Cells 3:1, pages 53-78.
Crossref
Serena Mazzucchelli. (2014) Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?. World Journal of Pharmacology 3:4, pages 72.
Crossref
Andrej Gorbatenko, Christina W. Olesen, Nina M⊘rup, Gerald Thiel, Tuula Kallunki, Eivind Valen & Stine F. Pedersen. (2013) ErbB2 upregulates the Na + ,HCO 3 ‐ ‐cotransporter NBCn1/ SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Krüppel‐like factor 4 . The FASEB Journal 28:1, pages 350-363.
Crossref
Filippo Montemurro & Maurizio Scaltriti. (2014) Biomarkers of drugs targeting HER-family signalling in cancer. The Journal of Pathology 232:2, pages 219-229.
Crossref
Jung Min Nam, Kyung-Hwa Jeon, Hanbyeol Kwon, Eunyoung Lee, Kyu-Yeon Jun, Yeung Bae Jin, Yun-Sil Lee, Younghwa Na & Youngjoo Kwon. (2013) Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity via suppression of HER2 expression and HER2-mediated signals in HER2-overexpressing breast cancer cells. European Journal of Pharmaceutical Sciences 50:2, pages 181-190.
Crossref
Abdullah Alajati, Nina Sausgruber, Nicola Aceto, Stephan Duss, Sophie Sarret, Hans Voshol, Debora Bonenfant & Mohamed Bentires-Alj. (2013) Mammary Tumor Formation and Metastasis Evoked by a HER2 Splice Variant. Cancer Research 73:17, pages 5320-5327.
Crossref
Juliane M. Krüger, Marlene Thomas, René Korn, Gabriele Dietmann, Christoph Rutz, Gero Brockhoff, Katja Specht, Max Hasmann & Friedrich Feuerhake. (2013) Detection of Truncated HER2 Forms in Formalin-Fixed, Paraffin-Embedded Breast Cancer Tissue Captures Heterogeneity and Is Not Affected by HER2-Targeted Therapy. The American Journal of Pathology 183:2, pages 336-343.
Crossref
S.M. Tolaney, J. Najita, J. Sperinde, W. Huang, W.Y. Chen, J. Savoie, M. Fornier, E.P. Winer, C. Bunnell & I.E. Krop. (2013) A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Annals of Oncology 24:7, pages 1841-1847.
Crossref
Kelly A. Whelan, Luciana P. Schwab, Sergey V. Karakashev, Lisa Franchetti, Gregg J. Johannes, Tiffany N. Seagroves & Mauricio J. Reginato. (2013) The Oncogene HER2/neu (ERBB2) Requires the Hypoxia-inducible Factor HIF-1 for Mammary Tumor Growth and Anoikis Resistance. Journal of Biological Chemistry 288:22, pages 15865-15877.
Crossref
T M Ward, E Iorns, X Liu, N Hoe, P Kim, S Singh, S Dean, A-M Jegg, M Gallas, C Rodriguez, M Lippman, R Landgraf & M D Pegram. (2012) Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5. Oncogene 32:19, pages 2463-2474.
Crossref
Swarnali Acharyya. (2013) Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression. Breast Cancer Research 15:2.
Crossref
David P. Boyle, Paul Mullan & Manuel Salto-Tellez. (2013) Molecular mapping the presence of druggable targets in preinvasive and precursor breast lesions: A comprehensive review of biomarkers related to therapeutic interventions. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1835:2, pages 230-242.
Crossref
Xiaohong Deng, Louise Fogh, Ulrik Lademann, Vibeke Jensen, Jan Stenvang, Huanming Yang, Nils Brünner & Anne-Sofie Schrohl. (2013) TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line. Tumor Biology 34:2, pages 1161-1170.
Crossref
B Morancho, J L Parra-Palau, Y H Ibrahim, C Bernadó Morales, V Peg, J J Bech-Serra, A Pandiella, F Canals, J Baselga, I Rubio & J Arribas. (2012) A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. Oncogene 32:11, pages 1452-1459.
Crossref
Dhong Hyo Kho, Pratima Nangia-Makker, Vitaly Balan, Victor Hogan, Larry Tait, Yi Wang & Avraham Raz. (2013) Autocrine Motility Factor Promotes HER2 Cleavage and Signaling in Breast Cancer Cells. Cancer Research 73:4, pages 1411-1419.
Crossref
Daniele Recupero, Lorenzo Daniele, Caterina Marchiò, Luca Molinaro, Isabella Castellano, Paola Cassoni, Alberto Righi, Filippo Montemurro, Piero Sismondi, Nicoletta Biglia, Giuseppe Viale, Mauro Risio & Anna Sapino. (2012) Spontaneous and pronase‐induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. The Journal of Pathology 229:3, pages 390-399.
Crossref
. 2013. DNA Repair and Cancer. DNA Repair and Cancer 115 118 .
Pier Davide Angelini, Mariano F. Zacarias Fluck, Kim Pedersen, Josep Lluís Parra-Palau, Marc Guiu, Cristina Bernadó Morales, Rocio Vicario, Antonio Luque-García, Nerea Peiró Navalpotro, Jordi Giralt, Francesc Canals, Roger R. Gomis, Josep Tabernero, José Baselga, Josep Villanueva & Joaquín Arribas. (2013) Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence. Cancer Research 73:1, pages 450-458.
Crossref
Claire Jackson, David Browell, Hannah Gautrey & Alison Tyson-Capper. (2013) Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance. International Journal of Cell Biology 2013, pages 1-8.
Crossref
Ricardo H Alvarez, Javier Cortés, Leticia De Mattos-Arruda, Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni, Nadia Harbeck, Martine Piccart, Stefania Zambelli & Dimitrios ZardavasMary Falzon & Michael Gandy. 2013. Handbook of HER2-targeted agents in breast cancer. Handbook of HER2-targeted agents in breast cancer 13 24 .
Agnieszka M Zagozdzon, Patrick O’Leary, John J Callanan, John Crown, William M Gallagher & Radoslaw Zagozdzon. (2012) Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice. BMC Cancer 12:1.
Crossref
Frank J. Lowery & Dihua Yu. (2012) Growth factor signaling in metastasis: current understanding and future opportunities. Cancer and Metastasis Reviews 31:3-4, pages 479-491.
Crossref
Rita Nahta. (2012) Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncology 2012, pages 1-16.
Crossref
D. Kostyal, R. S. Welt, J. Danko, T. Shay, C. Lanning, K. Horton & S. Welt. (2011) Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling. Medical Oncology 29:3, pages 1486-1494.
Crossref
Eylem Aydoğdu, Anne Katchy, Efrosini Tsouko, Chin-Yo Lin, Lars-Arne Haldosén, Luisa Helguero & Cecilia Williams. (2012) MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis 33:8, pages 1502-1511.
Crossref
Fabio Puglisi, Alessandro Marco Minisini, Carmine De Angelis & Grazia Arpino. (2012) Overcoming Treatment Resistance in HER2-Positive Breast Cancer. Drugs 72:9, pages 1175-1193.
Crossref
Chantal Tsé, Anne-Sophie Gauchez, William Jacot & Pierre-Jean Lamy. (2012) HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer. Cancer Treatment Reviews 38:2, pages 133-142.
Crossref
Jason A Wilken, Tayf Badri, Sarah Cross, Rhoda Raji, Alessandro D Santin, Peter Schwartz, Adam J Branscum, Andre T Baron, Adam I Sakhitab & Nita J Maihle. (2012) EGFR/HER-targeted therapeutics in ovarian cancer. Future Medicinal Chemistry 4:4, pages 447-469.
Crossref
Federico Cappuzzo, Yong Gon Cho, Andrea Sacconi, Greta Alì, Olimpia Siclari, Matteo Incarbone, Annarita Destro, Luigi Terracciano, Gabriella Fontanini, Antonio Marchetti, Massimo Roncalli & Marileila Varella-Garcia. (2012) p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 7:3, pages 520-527.
Crossref
Dana M. Brantley-Sieders. (2012) Clinical relevance of Ephs and ephrins in cancer: Lessons from breast, colorectal, and lung cancer profiling. Seminars in Cell & Developmental Biology 23:1, pages 102-108.
Crossref
Valentina Ciravolo, Veronica Huber, Gaia C. Ghedini, Elisabetta Venturelli, Francesca Bianchi, Manuela Campiglio, Daniele Morelli, Antonello Villa, Pamela Della Mina, Sylvie Menard, Paola Filipazzi, Licia Rivoltini, Elda Tagliabue & Serenella M. Pupa. (2012) Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. Journal of Cellular Physiology 227:2, pages 658-667.
Crossref
Andrea L. A. Wong & Soo-Chin Lee. (2012) Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. International Journal of Breast Cancer 2012, pages 1-13.
Crossref
Kelly M. Quesnelle & Jennifer R. Grandis. (2011) Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance . Clinical Cancer Research 17:18, pages 5935-5944.
Crossref
M. Bates, J. Sperinde, W.J. Köstler, S.M. Ali, K. Leitzel, E.M. Fuchs, A. Paquet, Y. Lie, T. Sherwood, R. Horvat, C.F. Singer, J. Winslow, J.M. Weidler, W. Huang & A. Lipton. (2011) Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Annals of Oncology 22:9, pages 2014-2020.
Crossref
Radoslaw Zagozdzon, William M. Gallagher & John Crown. (2011) Truncated HER2: implications for HER2-targeted therapeutics. Drug Discovery Today 16:17-18, pages 810-816.
Crossref
Wenle Xia, Zuguo Liu, Rongrong Zong, Leihua Liu, Sumin Zhao, Sarah S. Bacus, Yubin Mao, Jia He, Julia D. Wulfkuhle, Emanuel F. PetricoinIIIIII, Takuya Osada, Xiao-Yi Yang, Zachary C. Hartman, Timothy M. Clay, Kimberly L. Blackwell, Herbert K. Lyerly & Neil L. Spector. (2011) Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors. Molecular Cancer Therapeutics 10:8, pages 1367-1374.
Crossref
Cristina Marchini, Federico Gabrielli, Manuela Iezzi, Santa Zenobi, Maura Montani, Lucia Pietrella, Cristina Kalogris, Anna Rossini, Valentina Ciravolo, Lorenzo Castagnoli, Elda Tagliabue, Serenella M. Pupa, Piero Musiani, Paolo Monaci, Sylvie Menard & Augusto Amici. (2011) The Human Splice Variant Δ16HER2 Induces Rapid Tumor Onset in a Reporter Transgenic Mouse. PLoS ONE 6:4, pages e18727.
Crossref
J Malapeira, C Esselens, J J Bech-Serra, F Canals & J Arribas. (2010) ADAM17 (TACE) regulates TGFβ signaling through the cleavage of vasorin. Oncogene 30:16, pages 1912-1922.
Crossref
Joaquín Arribas, José Baselga, Kim Pedersen & Josep Lluís Parra-Palau. (2011) p95HER2 and Breast Cancer. Cancer Research 71:5, pages 1515-1519.
Crossref
Wolfgang J. Köstler & Yosef Yarden. 2011. Drugs for HER-2-positive Breast Cancer. Drugs for HER-2-positive Breast Cancer 1 32 .
Josep Lluís Parra-Palau, Kim Pedersen, Vicente Peg, Maurizio Scaltriti, Pier Davide Angelini, Marta Escorihuela, Sandra Mancilla, Alexandre Sánchez Pla, Santiago Ramón y Cajal, José Baselga & Joaquín Arribas. (2010) A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers. Cancer Research 70:21, pages 8537-8546.
Crossref
Giuseppe Viale, Mariacristina Ghioni & Mauro G Mastropasqua. (2010) Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies. Current Opinion in Oncology 22:6, pages 541-546.
Crossref
Jason A. Wilken & Nita J. Maihle. (2010) Primary trastuzumab resistance: new tricks for an old drug. Annals of the New York Academy of Sciences 1210:1, pages 53-65.
Crossref
Gaia C. Ghedini, Valentina Ciravolo, Monica Tortoreto, Sarah Giuffrè, Francesca Bianchi, Manuela Campiglio, Mimosa Mortarino, Mariangela Figini, Angela Coliva, Maria L. Carcangiu, Milvia Zambetti, Tiziana Piazza, Silvano Ferrini, Sylvie Ménard, Elda Tagliabue & Serenella M. Pupa. (2010) Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. Journal of Cellular Physiology 225:1, pages 256-265.
Crossref
Ellen Q. Ingalla, Jamie K. Miller, Jessica H. Wald, Heather C. Workman, Rouminder P. Kaur, Lily Yen, William H.D. Fry, Alexander D. Borowsky, Lawrence J.T. Young, Colleen Sweeney & Kermit L. CarrawayIIIIII. (2010) Post-transcriptional Mechanisms Contribute to the Suppression of the ErbB3 Negative Regulator Protein Nrdp1 in Mammary Tumors. Journal of Biological Chemistry 285:37, pages 28691-28697.
Crossref
Joaquín Arribas, Josep Lluís Parra-Palau & Kim Pedersen. (2010) HER2 Fragmentation and Breast Cancer Stratification. Clinical Cancer Research 16:16, pages 4071-4073.
Crossref
Jeff Sperinde, Xueguang Jin, Jayee Banerjee, Elicia Penuel, Anasuya Saha, Gundo Diedrich, Weidong Huang, Kim Leitzel, Jodi Weidler, Suhail M. Ali, Eva-Maria Fuchs, Christian F. Singer, Wolfgang J. Köstler, Michael Bates, Gordon Parry, John Winslow & Allan Lipton. (2010) Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients. Clinical Cancer Research 16:16, pages 4226-4235.
Crossref
Maurizio Scaltriti, Sarat Chandarlapaty, Ludmila Prudkin, Claudia Aura, José Jimenez, Pier Davide Angelini, Gertrudis Sánchez, Marta Guzman, Josep Lluis Parra, Catherine Ellis, Robert Gagnon, Maria Koehler, Henry Gomez, Charles Geyer, David Cameron, Joaquin Arribas, Neal Rosen & José Baselga. (2010) Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research 16:9, pages 2688-2695.
Crossref
S Chandarlapaty, M Scaltriti, P Angelini, Q Ye, M Guzman, C A Hudis, L Norton, D B Solit, J Arribas, J Baselga & N Rosen. (2009) Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29:3, pages 325-334.
Crossref
Moïse Namer, Michel Héry, Marc Spielmann & Joseph GligorovJ.-M. Ferrero & J. Barrière. 2010. Cancer du sein en situation métastatique. Cancer du sein en situation métastatique 439 451 .
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning & Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, pages 6-22.
Crossref
Jesús García-Castillo, Kim Pedersen, Pier-Davide Angelini, Joan Josep Bech-Serra, Núria Colomé, Matthew Paul Cunningham, Josep Lluis Parra-Palau, Francesc Canals, José Baselga & Joaquín Arribas. (2009) HER2 Carboxyl-terminal Fragments Regulate Cell Migration and Cortactin Phosphorylation. Journal of Biological Chemistry 284:37, pages 25302-25313.
Crossref
William J. Gullick. (2009) The epidermal growth factor system of ligands and receptors in cancer. European Journal of Cancer 45, pages 205-210.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.